The role of oxidative abnormalities in the pathophysiology of Alzheimer's disease
- PMID: 1962057
The role of oxidative abnormalities in the pathophysiology of Alzheimer's disease
Abstract
Several lines of evidence suggest that abnormalities in oxidative metabolism and specifically in mitochondria may play an important role in Alzheimer's disease. Abnormalities of oxidative metabolism exist in this disorder. They have been demonstrated in brain studied in vivo, ex vivo (biopsies), at autopsy, and in non-neural tissues including cultured cells. The abnormalities include a profound deficit in the activity of the ketoglutarate dehydrogenase complex (KGDHC), which is likely to lead to impaired metabolism of glutamate and might contribute to selective neuronal cell death by excitotoxic mechanisms as well as by direct effects on energy metabolism through its role in the tricarboxylic acid cycle. Abnormalities in oxidative metabolism may be related to the pathophysiology of Alzheimer's disease by plausible mechanisms for which there is evidence at least in model systems. Hypoxia is known to induce neuropsychological impairments analogous to those which occur in dementing syndromes. Brain, and specifically neurons, are likely to be particularly vulnerable to impairments of oxidative metabolism because of their demonstrated tight dependence on continuous oxidation of glucose to maintain their structure and function. Neuroanatomic studies as well as recent data from CT, PET, and SPECT scanning agree with formulations that suggest the brain areas of greatest vulnerability in Alzheimer's disease include those particularly sensitive to oxidative impairments. Although the mechanisms of accumulation of the classical neuropathological hallmarks of Alzheimer's disease (paired helical filaments, amyloid plaques) are not known, experimental data suggest that metabolic stresses may contribute to the accumulation of these materials. These data include the accumulation of immunoreactivity of anti-paired helical filament antibodies in cells exposed to a mitochondrial poison, the uncoupler CCCP. Impairments of oxidative metabolism are known to impair the metabolism of neurotransmitters involved in Alzheimer's disease; the synthesis of acetylcholine, which is characteristically involved, is exquisitely sensitive to oxidative abnormalities. Experimental evidence suggests that abnormalities of cellular calcium homeostasis, which have been demonstrated in Alzheimer cells, may mediate key deleterious effects of the abnormalities in oxidative metabolism in this disorder. Experimental studies in animals indicate that age potentiates the effects of inherent oxidative abnormalities on the brain, as does cerebrovascular disease. These observations might help to explain the increasing clinical expression of the gene for Alzheimer's disease with age. They are also in accord with difficulties in separating the role of vascular from that of inherent degenerative factors in dementia of later onset. Treatment with L-carnitine, a manipulation designed to mitigate consequences of a mitochondrial abnormality, normalized several non-mitochondrial abnormalities in cultured Alzheimer cells.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Mitochondria as a primary target for vascular hypoperfusion and oxidative stress in Alzheimer's disease.Mitochondrion. 2004 Sep;4(5-6):649-63. doi: 10.1016/j.mito.2004.07.018. Mitochondrion. 2004. PMID: 16120422
-
Brain mitochondrial dysfunction as a link between Alzheimer's disease and diabetes.J Neurol Sci. 2007 Jun 15;257(1-2):206-14. doi: 10.1016/j.jns.2007.01.017. Epub 2007 Feb 20. J Neurol Sci. 2007. PMID: 17316694 Review.
-
Mitochondrial aging and dysfunction in Alzheimer's disease.Prog Neuropsychopharmacol Biol Psychiatry. 2005 Mar;29(3):407-10. doi: 10.1016/j.pnpbp.2004.12.007. Prog Neuropsychopharmacol Biol Psychiatry. 2005. PMID: 15795049 Review.
-
Altered metabolic properties of cultured skin fibroblasts in Alzheimer's disease.Ann Neurol. 1987 May;21(5):451-7. doi: 10.1002/ana.410210507. Ann Neurol. 1987. PMID: 3109316
-
Therapeutic potential of oxidant mechanisms in Alzheimer's disease.Expert Rev Neurother. 2004 Nov;4(6):995-1004. doi: 10.1586/14737175.4.6.995. Expert Rev Neurother. 2004. PMID: 15853526 Review.
Cited by
-
Neuroprotective effect of leukemia inhibitory factor on antimycin A-induced oxidative injury in differentiated PC12 cells.J Mol Neurosci. 2013 Jul;50(3):577-85. doi: 10.1007/s12031-013-0004-x. Epub 2013 May 1. J Mol Neurosci. 2013. PMID: 23636893
-
Mitochondrial Alpha-Keto Acid Dehydrogenase Complexes: Recent Developments on Structure and Function in Health and Disease.Subcell Biochem. 2024;104:295-381. doi: 10.1007/978-3-031-58843-3_13. Subcell Biochem. 2024. PMID: 38963492 Review.
-
Amyloid beta-peptide(1-42) contributes to the oxidative stress and neurodegeneration found in Alzheimer disease brain.Brain Pathol. 2004 Oct;14(4):426-32. doi: 10.1111/j.1750-3639.2004.tb00087.x. Brain Pathol. 2004. PMID: 15605990 Free PMC article. Review.
-
Metabolic Abnormalities of Erythrocytes as a Risk Factor for Alzheimer's Disease.Front Neurosci. 2018 Jan 5;11:728. doi: 10.3389/fnins.2017.00728. eCollection 2017. Front Neurosci. 2018. PMID: 29354027 Free PMC article. Review.
-
Plasma thiamine deficiency associated with Alzheimer's disease but not Parkinson's disease.Metab Brain Dis. 1998 Mar;13(1):43-53. doi: 10.1023/a:1020678912330. Metab Brain Dis. 1998. PMID: 9570639
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical